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ABSTRACT
Coronavirus Disease 2019 (COVID-19) has emerged in Wuhan, China, in December 2019,
then spread to become a worldwide pandemic with significant morbidity and mortality. This has
left healthcare systems worldwide vulnerable to the surge in the number of patients. With the exponential spread of the disease and increasing demand for medical care, a significant proportion of
medical procedures were canceled or delayed to decrease viral transmission. Most inflammatory
bowel disease patients are on immunosuppressive agents, which are presumed to put them at a
higher risk for acquiring the infection. However, some studies have shown that immunosuppressive
agents did not increase mortality from COVID-19 at any age. Although most of the morbidity and
mortality of this condition are related to respiratory manifestations, some patients develop extrapulmonary manifestations including gastrointestinal and hepatic derangements. Studies have shown
that liver chemistry abnormalities are common with COVID-19. There is currently no vaccine or
effective treatment for COVID-19, so the only thing we can do is reduce the virus's transmission.
In this review, we addressed the dilemma of how to deal with gastroenterological procedures in
times of a spreading pandemic, to decide which procedures can or cannot be postponed based on
current international available data. As well as, to ensure the continuation of the essential management of inflammatory bowel diseases (IBDs) patients, many of whom are on immunosuppressive
and biologic agents, thus, making the decisions about which medications the patient can stay on to
prevent disease attacks. Finally, studying the hepatic manifestations during the COVID-19 pandemic. We have also postulated local recommendations that can serve as a guide for managing liver
diseases during COVID-19 and when to go to liver transplantation with the least risk possible for
viral transmission.
Keywords: Coronavirus, COVID-19, Gastroenterological procedures, Inflammatory Bowel
Diseases, Liver disease, Liver transplantation.
The increasing need for hospitalizations and
INTRODUCTION
intensive care unit admissions has urged
Coronaviruses are enveloped in nonhealth care systems around the world to cansegmented positive-sense RNA viruses. The
cel or postpone elective procedures in prepanew 2019 novel coronavirus (2019-nCoV),
ration for the expected surge in cases [4].
has emerged in Dec 2019 in China and has
COVID-19 pneumonia is presumed to
been declared in March 2020 by the World
spread primarily by respiratory droplets (e.g.,
Health Organization (WHO) as a pandemic
sneezing, coughing, etc.) [5]. Considering
[1, 2]. Globally, over 55 million confirmed
close person-to-person contact puts the indicases of COVID-19 have been reported. The
vidual at a higher risk of contracting the disreported cases of Coronavirus disease 2019
ease, health care professionals involved in
(COVID-19) in occupied Palestinian territory
direct clinical care, and those involved with
based on WHO data, were 93,700 confirmed
procedural medicine are at high risk of decases in West Bank including Jerusalem, and
veloping COVID-19. It is estimated that 10%
27,400 confirmed cases in Gaza Strip [3].
of the health care professionals have become
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infected with the virus in western countries
[6].

experts followed the previous regional guidelines associated with COVID-19 [8, 9].

The spread of the disease via health care
workers is particularly concerning because of
the following reasons: 1) Scarcity of Personal
Protective Equipment (PPE), 2) Shortage of
healthcare workers due to illness or quarantine, 3) Concern for healthcare workers becoming vectors for transmission of the
COVID-19 virus, and 4) Individuals, including health care workers, can be contagious
without displaying any signs or symptoms of
the disease [2, 7].

Gastroenterological
COVID-19

This study aims to address how to deal
with gastroenterological procedures during
the spreading pandemic with the least risk for
viral transmission and classify the procedures
to which can be postponed and that cannot be
delayed based on current international available data and expert experience. Our second
objective was recommendations concerning
the management of inflammatory bowel diseases (IBDs) during the current pandemic to
clarify which drugs should be continued to
prevent IBD relapse or stopped to decrease
viral transmission risk. Finally, we studied
the approach and screening protocol to
COVID-19 with liver function test abnormality. Also, we think that we should have regional guidance regarding liver diseases
drugs continuation, drug-drug interactions,
hepatitis reactivation, and doing or delaying
liver transplantation.
METHODS
To date, the guidelines for dealing with
gastroenterological procedures, managing
inflammatory bowel diseases, managing liver
diseases, and dealing with liver transplantation patients before and after transplant in
patients with COVID-19 have already been
established globally; however, there are no
regional guidelines. Thus, the An-Najah National University Hospital gastroenterology
and internal medicine expert group collected
and summarized the current international
available data of different literature and
guidelines among different databases comprising Google Scholar, Medline, Pub Med,
EMBASE, and Science Direct. Also, data
obtained from WHO to create these recommendations in patients with COVID-19. The

procedures

and

While direct person-to-person contact
puts the individual at higher risk of contracting the disease, aerosol-generating medical
procedures generate small droplets and permit the virus's airborne transmission. Esophagogastroduodenoscopy (EGD), small bowel
enteroscopy, endoscopic ultrasound (EUS),
endoscopic retrograde cholangiopancreatography (ERCP), and esophageal manometry
are some of the aerosol-generating procedures that should be considered as high risk
for viral transmission [4].
It is likely that COVID-19 will remain
an issue for the foreseeable future and that it
has and will continue to have a negative impact on our healthcare systems including its
endoscopy capacity and its ability to deliver
medical services on time. With a steadily
rising number of COVID-19 cases around the
globe, it is difficult to determine the appropriate time to resume medical services in endoscopy centers.
Considering the points mentioned above,
we summarized the following recommendations for gastroenterological procedures during the COVID-19 pandemic to mitigate the
virus's transmission.
Triage patients before scheduling an appointment
Telephoning the patient to ask about
symptoms and signs of COVID-19 pneumonia before an appointment is made and 3 days
before the procedure is planned along with
using the (FTOCC) triage (Fever of more
than 37.5 C, Travel history, Occupational
exposure, Contact history, and Clustering
type) can help in classifying the patients into
high-risk and low-risk groups for having the
virus [10]. This recommendation aims to ration the valuable resources at a time where
they could be used more effectively to protect healthcare professionals while interacting
with higher-risk patients.
All patients suspected to have coronavirus based on the mentioned screening tool
should be offered a Real-Time Polymerase
Chain Reaction (RT-PCR) antigen testing
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before presenting to do the procedure, their
procedure should be deferred for 14 days
where clinically appropriate. It should have
their procedure performed in a high risk or
hot unit to minimize interaction between
high-risk and low-risk patients.
On the day of the procedure
Dealing with patients should be done
with caution at all times so we recommend
using surgical masks by healthcare professionals and patients, maintaining a distance
by staying at least two meters apart whenever
possible, and using a physical barrier such as
a face shield. These measures should be stuck
to at all times including but not limited to the
following interactions: patient assessment,
taking vital signs, and informed consent for
the procedure. Screening tools should also be
implemented to risk stratify the patients and
minimize interaction with high-risk patients.
For patients deemed at high risk of having COVID-19, we recommend using a separate unit for performing the procedure if
available. As resources have been becoming
more scarce since the beginning of this pandemic and a separate unit might not be available, using separate pre and post-endoscopy
recovery areas might be an alternative. It is
reasonable to postpone high-risk or COVID19 positive patients at the end of the session.
Using full PPE, including N95 respirator
cannot be overemphasized and, where available, negative pressure rooms for performing
high-risk aerosol-generating procedures on
the high-risk patient [11].
For all patients, including those with
low-risk, standard precautions should be implemented at all times including keeping a
distance of 2 meters, using surgical masks,
rigorous hand hygiene. Considering the urgency of the pandemic in the current period
and lack of a reliable r
apid COVID-19 test, only experienced
endoscopists, anesthetists, and healthcare
professionals should be present during the
procedure. To minimize exposure, only personnel directly involved in the procedure
should be present once the patient enters the
endoscopy unit. It is important to keep ample
time before and after the procedure for infection control measures.

Urgent, Semi-urgent and Non-Urgent Procedures
In general, Gastroenterological procedures can be divided into Urgent, Semiurgent, and Elective (non-urgent) procedures
according to the Asian Pacific Society for
Digestive Endoscopy [12], please refer to
figure 1.
Abbreviations: EMR (Endoscopic mucosal resection).
Needless to say, urgent procedures
should be performed urgently but while using
full protective equipment especially since the
information is likely to be lacking on the risk
of having COVID19. Likewise, Elective procedures can be postponed during the current
surge of the virus after setting a new appointment or by using telemedicine. Semiurgent procedures need a discussion on a
case-by-case basis to decide on the urgency
of the procedure. Figure 2 gives an algorithm
on how to proceed when endoscopy is indicated.
Following the procedure
Standard cleaning and sterilization of the
endoscopy unit and tools as per the American
Society for Gastrointestinal Endoscopy
guidelines has proven effective at deactivating coronaviruses [13].
Commonly used biocidal agents including hydrogen peroxide, alcohols, sodium hypochlorite, and benzalkonium chloride have
been confirmed to decontaminate surfaces
and tools from coronaviruses [14]. For infection control during GI endoscopy current
guidelines Include mechanical and detergent
cleaning, followed by high-level disinfection
(HLD), rinsing and drying through sterilization.
Follow up phone calls at 7- and 14-days
post endoscopy to inquire about COVID19
symptoms or positive testing is useful to determine if an endoscopy unit has been exposed to the virus and to take protective action in a timely manner to minimize exposure
to other units and patients.
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Gastroenterological
procedures

Urgent
Procedures

Non-urgent
procedures

Semi-urgent
Procedures

Include:
. All routine symptomatic
referrals
. Elective interventions
(e.g. pneumatic dilation,
stricture dilation)
. Bariatric endoscopy
. Low-risk follow-up
scopes (e.g. esophagitis
heal, gastric ulcer heal,
poor views).

Include:
. 2 week wait cancer referrals
. Planned Endoscopic
. EMR for complex polyps,
new suspected
. Inflammatory Bowel disease
. Small bowel enteroscopy
for occult small bowel
bleeding.

Include:
. Acute gastrointestinal
bleeding
. Biliary Sepsis
. Management of perforation or leakage
. Acute esophageal
obstruction (e.g. foreign
body, food bolus)
. Urgent inpatient nutritional support.

Figure )1(: Gastroenterological procedures classification according to the Asian Pacific Society for
Digestive Endoscopy.
Should I perform the
endoscopic procedure?
Procedure is not
urgent or adequate
PPEs not available

None

Determine the time-sensitive
nature of the procedure, to
be performed within 24 hours
or 8 weeks

ئ

If unsure, consider the following:
1- Telephone consultation with
referring physician
2- Telehealth visit with the patient
3- Multidisciplinary team approach
or virtual tumor board

Either or
both

Delay procedure and reassess at 8
weeks, Examples:
 Screening Colonoscopy
 EGD for Dysplasia
 Colonoscopy
following fecal
occult blood positive test

Within 24 hours:
Cholangitis, Upper GI
Bleeding, Food Impaction
Within 8 weeks: Lower GI
Bleeding, Sigmoidoscopy for evaluation of Ulcerative Colitis

Figure )2(: How to proceed when endoscopy is indicated.
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Abbreviations: PPEs (personal protective
equipment's), EGD (Esophagogastroduodenoscopy), GI (Gastrointestinal).
Inflammatory Bowel Disease (IBD) and
COVID-19
As the outbreak spread to a worldwide
pandemic, concerns that immunocompromised patients may be at high risk of developing coronavirus disease 2019 (COVID-19)
were raised [15]. The treatment regimens for
inflammatory bowel disease (IBD) patients
comprising Crohn’s disease (CD) and ulcerative colitis (UC), frequently involve immunosuppressive and/or biologic agents which are
known to increase a patient's susceptibility to
certain infections. We have gathered the
available evidence on COVID-10 and its impact on IBD patients [16].
In contrast to those with comorbidities
like diabetes, heart disease, lung disease, or
kidney disease which are considered as risk
factors for poor outcomes. Patients with impaired or suppressed immune response are
not at a higher risk for severe or complicated
COVID-19 infection [17].
One study conducted in Italy during the
COVID-19 pandemic supports the above-

mentioned statement where 522 patients with
inflammatory bowel disease were followed
over one month (Feb-March 2020) [18]. Another similar study conducted in Wuhan and
involved 319 patients with IBD reported no
Confirmed COVID-10 cases of pneumonia in
the IBD population [19]. This comes because
no treatment regimens were adjusted [18,
19]. This was also true for the two previous
epidemics caused by coronaviruses, Middle
East respiratory syndrome caused by the
coronavirus named MERS-CoV, and severe
acute respiratory syndrome-associated coronavirus (SARS-CoV).
After a careful review of SARS-CoV
mortality and morbidity reports, there is no
mentioned report to link immunosuppression
(including patients on immunosuppressive or
chemotherapeutic medications and transplant
recipients) as a risk factor for mortality at any
age wither in the current pandemic or the
previous coronavirus outbreaks [17, 18, 20].
Taking into account the previously mentioned points, we have gathered the following
recommendations concerning the management of IBD during the current pandemic.
Figure 2 summarizes those recommendations.

IBD patient with Upper
respiratory or GI symptoms
Test for COVID-19 &
Disease Relapse (CRP,
Fecal Calprotectin)

COVID-19 Negative
& IBD Relapse
Unlikely

 Consider repeat
COVID-19 Testing
 Consider other causes
(Gastroenteritis,
Clostridium
Colitis) and
treat accordingly
 Avoid hospitalization
if feasible

COVID-19 Positive
& IBD Relapse
Likely

 Focus on the more
severe illness
 Avoid Methotrexate,
Thiopurines
 Hold Biologics as long as
COVID-19 active
 Continue 5-ASA,
Budesonide,
Rectal therapies
 Focus on life support
and COVID-19 management

COVID-19 Positive
& IBD Relapse
Unlikely

 Treat for COVID-19
as per local protocol
 Avoid Thiopurines,
Methotrexate,
 Hold Biologics as long as
COVID-19 active
 Continue 5-ASA
Budesonide, Rectal
therapies
 Focus on life support and
COVID-19
management

COVID-19 Negative &
IBD Relapse
Likely

 Consider Repeat
COVID-19 Testing
 Consider medication
adherence and
medication levels
 Treat on Risk-Benefit basis
 Consider rectal therapies
&Budesonide
 Avoid Methotrexate,
Thiopurines, Biologics

Figure )3(: Management of IBD during the COVID-19
Pandemic.
Avoid Thiopurines,
Methotrexat,
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long as COVID-19
active
Continue 5-ASA
Budesonide, Rectal
therapies
Focus on life
support and
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Abbreviations: CRP (C-reactive protein),
IBD (Inflammatory bowel disease), 5-ASA
(5-aminosalicylic acid).
minosalicylic Acid Derivative
We recommend that 5-aminosalicylic acid (5-ASA) (e.g. Mesalazine and sulfasalazine) should be continued as there is no data
to support discontinuation of either oral or
rectal preparations. This recommendation
includes patients with symptoms suspicious
of COVID-19 (such as new cough, fever of
more than 100F, breathlessness) or even patients who tested positive for the disease [21].
Corticosteroids
In COVID-19 negative patients, it is recommended to avoid corticosteroids whenever
possible especially in co-administration with
other immunosuppressive agents. In the case
of IBD relapse, corticosteroids use may be
unavoidable. In such scenarios, consider using locally acting preparations. Systemic
steroids should be prescribed after careful
assessment of risks and benefits [21]. In patients with symptoms suspicious of COVID19 and those confirmed to have the disease,
systemic steroids should be used at a low
dose and discontinued once the risks outweigh their benefit. However, tapering steroids could be used when other alternatives
are unavailable or cannot be used [22]. According to the local corticosteroids
(Budesonide, Beclomethasone dipropionate)
should be continued regardless of the
COVID-19 status [21].
Immunomodulatory
pressive agents)

drugs

(immunosup-

Immunomodulatory drugs including thiopurines
(e.g.
Azathioprine,
6mercaptopurine), methotrexate and calcineurin inhibitors (e.g. Cyclosporine) should be
continued to decrease the risk of disease recurrence, especially in COVID-19 negative
patients as well as those with no symptoms of
COVID-19 infection [16, 21, 22]. In highrisk endemic areas, changing the dose or the
medication is not recommended unless clinically indicated [23]. Starting a new biologic
agent could be sought if protective and supportive measures are available [16]. We believe that continuing immunomodulatory

drugs would lead to the possibility of the rapid evolution of the infection so immunomodulatory treatments should be discontinued in
the case of a positive test throughout the infection [21]. This does not include patients
with a high risk of relapse (i.e. history of intestinal or colonic stricture, intra-abdominal
abscesses or fistulae, complex perianal or
severe rectal disease).
Biologic therapy and small molecule
The available data suggests that the risk
of COVID-19 infection and its complications
is not increased in IBD patients receiving
biological treatment. Consequently, biological agents including (1) anti-TNF (Tumor
necrosis factor) agents (e.g. infliximab and
adalimumab), (2) anti-integrin (e.g. vedolizumab) and (3) anti-interleukin (e.g. ustekinumab) should be continued in COVID-19
negative patients. The risks and benefits of
discontinuing those biological agents should
be balanced to avoid the risk of disease relapse. This recommendation also applies to
small molecule drugs (JAK inhibitors e.g.
tofacitinib and baricitinib). However, in the
case of a positive test, biological agents and
small molecule drugs should be discontinued
throughout the infection [21, 22].
Liver diseases and COVID-19
Recent studies indicated that 50-76% of
patients with COVID-19 have elevated aspartate transaminase (AST) and alanine transaminase (ALT) during their illness [24, 25]. It's
been shown that elevations of ALT & AST
correlate with the severity of COVID-19 infection [26]. Though most COVID-19 patients have only mild elevations of Liver enzymes (i.e. 1-2 times the upper limit of normal).
It is recommended that every patient
with COVID-19 infection and liver enzyme
derangement undergo screening protocol (according to local prevalent causes) to establish
the etiology of liver injury as multiple etiologies could be responsible including but not
limited to COVID-19 or its complications,
drug-induced or underlying liver disease.
Therefore, establishing the cause behind the
liver injury will facilitate management and
reduce overall mortality and morbidity. In
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Asia, for example, the high prevalence of
Hepatitis B & C Viruses, Alcohol-related
liver disease, and Nonalcoholic Fatty Liver
Disease (NAFLD) necessitates directing
screening protocol towards these etiologies
[27-29]. Screening for other causes of liver

injury is only necessary when liver test abnormalities persist beyond recovery of
COVID-19. Figure 3 represents an approach
to COVID-19 patients with elevated liver
function
tests.

Liver function test abnormality in COVID-19 patient

Identify patient who have underlying
chronic liver disease

History and physical
Examination

Doppler ultrasound if there is
clinical suspicion of obstruction

ر

Search for other causes of
chronic liver disease according
to the clinical presentation e.g.
Autoimmune liver disease

ر

Hepatitis profile,
Metabolic panel

Review medications

ر

Discontinue the hepatotoxic
medication

ر

Manage the underlying cause
of chronic liver disease

ر

Manage COVID-19 as protocol

Figure )4(: Approach to COVID-19 patient with liver function test abnormality.
Considering that COVID-19 infection
can cause liver injury especially given that
the severity of COVID-19 pneumonia and
Liver injury is directly proportional, screening for Hepatitis-B Virus infection in all patients with severe COVID-19 pneumonia is
recommended and those found to be positive
should start antiviral prophylaxis with a nucleoside analogue [30].

There are no major drug-drug interactions between current therapeutic options for
COVID-19 and Nucleoside analogues used to
treat hepatitis-B viral infection. Therefore, no
absolute contraindications exist in the current
period regarding drug-drug interactions. Our
recommendation is to initiate or continue
treatment for hepatitis-B infection in a patient
being treated for COVID-19.

Immunosuppressive agents including
high dose systemic steroids and interleukin-6
(IL-6) monoclonal antibodies have been advocated for the treatment of critically ill
COVID-19 patients and were found to be
triggering factors for Hepatitis-B reactivation, chronic hepatitis-B infection flare, or
acute liver failure [31]. For that, screening
for hepatitis-B infection is recommended for
patients planned for such treatments, and
those found to be positive are recommended
to start antiviral prophylaxis with a nucleoside analogues.

Most current therapeutic options for
COVID-19 do not have significant drug-drug
interactions with direct-acting antivirals
against chronic hepatitis-C virus infection.
The only significant interaction possible is
the use of protease inhibitor direct-acting
antivirals with lopinavir-ritonavir which may
lead to a significant elevation in ALT. The
pathophysiology behind this is related to lopinavir’s ability to significantly increase the
blood concentration of protease inhibitors.
Therefore, the use of protease inhibitor direct-acting antivirals with lopinavir-ritonavir
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is contraindicated. Furthermore, Hepatitis-C
viral flare following termination of directacting antivirals is rare [32] and so, we recommend termination of or withholding direct-acting antivirals if a significant drugdrug interaction is discovered or if the patient
is in critical condition (e.g. requiring invasive
or non-invasive ventilation).
Patients with Non-Alcoholic Fatty Liver
Disease (NAFLD) have a higher probability
of having metabolic comorbidities, namely
Type II Diabetes Mellitus and Hypertension,
which places them at a higher risk of having
severe COVID-19 infection. Although studies looking into the severity of COVID-19
infection in patients with NAFLD are currently lacking, Diabetes is currently known to
increase the risk of Intensive care unit admission mechanical ventilation and death due to
COVID-19 [33]. As patients with NAFLD
are at higher risk of developing a druginduced liver injury, close monitoring of liver
function is advised in those patients.
Ever since the beginning of the pandemic, Screening protocols have been a center of
controversy and debate. Balancing the risk of
contracting COVID-19 infection and the risk
of developing the illness or complication under surveillance has been the target of many
researchers and clinicians. Hepatocellular
Carcinoma is the 3rd most common cause of
cancer-related death worldwide and early
detection increases the probability of curative
management and therefore decreases mortality [34]. Considering those facts, in regions
with a high prevalence of COVID-19 it is
reasonable to delay screening for Hepatocellular Carcinoma by 3 to 6 months depending
on the urgency of screening and availability
of resources including health-care staff. Although screening every 6 months is recommended, screening every 1 year is beneficial
with no difference in survival [35]. For patients diagnosed with stable Hepatocellular
Carcinoma but not COVID-19, continuous
follow up with telemedicine and AlphaFetoprotein (AFP) locally is recommended.
In patients with high risk for Hepatocellular Carcinoma (cirrhosis, chronic hepatitis
B) continue screening as planned if possible.
In such patients, a delay of 2 months is acceptable once risks and benefits are discussed

with the patient. Patients suspected to have
Hepatocellular Carcinoma due to elevated
AFP or Liver nodule should be prioritized.
For a patient confirmed to have Hepatocellular Carcinoma, surgical resection and liver
transplantation are the curative therapeutic
options available if the disease is detected in
its early stages. Considering COVID-19 is
highly contagious and most patients recover
within 2-4 weeks [33]. It is reasonable to defer treatment of Hepatocellular Carcinoma
for a few weeks after recovery while using
bridging therapy.
Bridging therapeutic options for Hepatocellular Carcinoma include transarterial
chemo-embolization, radio-frequency ablation, and systemic chemotherapy. Coupling
those options with close monitoring by using
imaging studies and AFP reduces the risk of
potential progression of the disease beyond
the eligibility for liver transplantation or resection.
We recommend continuing treatment for
Hepatocellular Carcinoma in COVID-19 free
patients as deemed appropriate. Patients already on kinase inhibitors may continue their
treatment given they are not infected with
COVID-19. Those who become infected
should withhold Hepatocellular Carcinoma
directed immunotherapy until resolution of
their infection.
Variceal bleeding is a potentially lifethreatening complication in patients with liver cirrhosis [36]. Prognosis is even poorer if
the patient presents with hemodynamic instability requiring urgent endoscopy [37]. Considering upper endoscopy is a high-risk procedure for transmission of COVID-19, patients planned for elective endoscopy who
have a low-risk of variceal bleeding might be
postponed. To identify patients with clinically significant varices and, hence, at high risk
of future variceal bleeding, we recommend
using non-invasive assessment methods with
good predictive value, including Baveno IV
criteria platelet-to-liver stiffness measurement ratio, liver stiffness measurement ratio,
and spleen stiffness measurement with transient electrography. This recommendation is
expected to reduce the need for upper endoscopy in 50% of the cases and therefore the
need for scarce personal protective equip-
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ment and personnel [38].

nolate mofetil. Reduce tacrolimus dose
by 2-5% of the baseline when using lopinavir-ritonavir [17, 39].

Liver transplantation and covid19
Liver transplantation is a curative therapeutic option for chronic liver disease. The
comorbidities that commonly accompany the
chronic liver disease, long term immunosuppressive therapy and regular follow up needed post-transplantation are risk factors for
developing COVID-19 and need to be taken
into consideration.
Given the whole picture, we composed the
following recommendations concerning liver transplantation
1.

2.

3.

Limiting liver transplantation to emergency cases (acute liver failure, high
MELD score, and high rate of progression to hepatocellular carcinoma) conforming to local resources and status of
the pandemic.
Before planned transplantation, the donor and recipient must be tested for
coronavirus with a nasopharyngeal swab,
bronchoalveolar lavage, or chest CT
keeping in mind that negative testing
does not rule out infection.
Risks of liver transplant in a COVID-19
positive patient should be balanced
against benefits taking into consideration
risks to healthcare personnel.

4.

No adjustment to immunosuppressive
medications is recommended in a
COVID-19 negative liver transplant patient as any adjustment carries the risk of
organ rejection.

5.

Consider immunosuppressive therapy
dose reduction in a patient with moderate COVID-19 infection. Doses are recommended to be reduced in patients with
lymphopenia, fever, or worsening pneumonia.

6.

Consider the risk of drug-drug interaction between immunosuppressive therapeutic medications and COVID-19 medications. Such risk is expected when using medications metabolized by Cytochrome P450 enzymes (sirolimus, tacrolimus) and lopinavir-ritonavir but no, or
minimal, interaction is expected with azathioprine, cyclosporine, and mycophe-

7.

Transplant recipients who develop severe COVID-19 infection should be
treated according to local protocol taking
into account drug interactions.

8.

Follow-up should be maintained through
altered pathways including telehealth/telephone consultation and local
blood testing, immediate medical attention must be provided when indicated.

9.

All liver transplant recipients should receive vaccination against influenza and
pneumococcal infection.

10. If a steroid dose reduction is decided, a
minimum of 10 mg daily of prednisone
or equivalent should be continued to
avoid adrenal insufficiency.
CONCLUSIONS
COVID-19 is a global pandemic with a
high morbidity and mortality rate, affecting
every aspect of the health system with an
ongoing shortage of healthcare workers under the continuous risk of contracting the virus.
This paper provides scientific evidence
in addition to expert opinion to guide the
health care team on how to deal with gastroenterological procedures, to clarify the effect
of COVID-19 on inflammatory bowel disease patients on immunosuppressive and biologic agents. Finally, it outlined a screening
protocol for liver disease in COVID-19 patients and provided a set of recommendations
concerning antiviral drugs and liver transplantation.
Our recommendations concerning gastroenterological procedures focused on
standard cleaning and sterilization of the endoscopy unit and tools. They also emphasized the importance of maintaining standard
precautions at all times and for all patients
including keeping a distance of 2 meters, using surgical masks, and rigorous hand washing or hygiene.
Concerning IBD management, immunosuppressive and biological drugs should not
be discontinued in patients asymptomatic for
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COVID-19 especially considering that immunosuppressive medications were not
shown to increase the risk of contracting
COVID-19 or its mortality.
Screening for hepatitis B infection is
recommended for patients planned for high
dose systemic steroids or interleukin-6 (IL-6)
monoclonal antibodies as these were found to
be triggering factors for Hepatitis B reactivation. Those found to be positive are recommended to start antiviral prophylaxis with a
nucleoside analogues.
Liver transplantation procedures should
be limited to emergency cases. Before the
procedure, the donor and recipient must be
tested for COVID-19 to avoid unnecessary
exposure. Generally speaking, immunosuppressive medications do not need to be adjusted solely to avoid COVID-19 infection or
complications.
These recommendations and algorithms
present an expert opinion that is based on a
careful review of the available data. It aims
to guide clinicians to provide excellent medical care with the least risk possible for viral
transmission. We aspire to have provided a
stepping stone to generating work protocols
at times of a pandemic.
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